- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00540007
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
October 5, 2017 updated by: Washington University School of Medicine
A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
Study Overview
Detailed Description
Hodgkin lymphoma (HL), an uncommon but significant subtype of lymphoma, is divided into classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL).
Progress has been made in cHL therapy resulting in 5-year failure free survival rates between 61%-89% even in the setting of advanced stage or bulky disease.
Patients who relapse however, have a variable prognosis ranging from a 8-year overall survival rate of less than 8% for patients who never achieve a remission to 54% for patients with a complete remission lasting greater than 12 months.
High dose chemotherapy with autologous stem cell support is the standard of care for patients with relapsed cHL but for those that relapse despite aggressive salvage therapy 20 - 50%, with median remission durations of approximately 6 months.
Furthermore, a subset of relapsed HL patients may not be candidates for aggressive salvage regimens.
These novel salvage therapies are needed for relapsed/refractory cHL, especially agents without serious late toxicities are particularly attractive in this disease.
Advances in the understanding of HL pathogenesis and lenalidomide's mechanisms of action provide substantial rationale for evaluating lenalidomide in HL patients.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Medical School
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- Ohio State University
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy.
- Patients must have relapsed or progressed after at least one prior systemic cytotoxic chemotherapy; prior autologous or allogeneic stem cell transplantation is allowed.
- Measurable disease must be present either on physical examination or imaging studies (CT, MRI, PET/CT). Any tumor mass greater or equal to 1 cm is acceptable.
- Age > 18 years old.
- ECOG performance status of less than or equal to 2 at study entry
Adequate hematologic, renal, hepatic function as defined by:
- Absolute neutrophil count greater than or equal to 1000 / uL
- Platelets greater than or equal to 50,000 / uL
- Serum creatinine less than or equal to 1.5X institution upper limit of normal (ULN)
- Total bilirubin less than or equal to 2.0 mg/dL
- AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN (if not attributed to cHL)
- Disease free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
- Understand and voluntarily sign an informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements
- Females of childbearing potential (FCBP)† must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
- FCBP must have two negative serum or urine pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
- Men must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight
- All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist.
Exclusion Criteria:
- Patients who are candidates for high dose chemotherapy and stem cell transplantation and have not yet undergone stem cell transplantation should not be enrolled.
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Any condition, including the presence of laboratory abnormalities.
- Use of any other anti-cancer drug or therapy, including experimental, within 30 days of enrollment.
- Known hypersensitivity to thalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Any prior use of lenalidomide.
- Known positive for HIV or infectious hepatitis, type A, B or C.
- Pregnant or breastfeeding females.
- Concurrent use of other anti-cancer agents or treatments.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 - Lenalidomide daily on days 1-21
|
Other Names:
|
Experimental: Cohort 2 - Lenalidomide daily on days 1-28
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL.
Time Frame: Through 3.5 years from study entry or until disease progression
|
|
Through 3.5 years from study entry or until disease progression
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of Lenalidomide Therapy as Measured by the Number of Participants Who Experience Each Adverse Event (Grade 3 or 4 Adverse Events Only) Refractory cHL.
Time Frame: 30 days following the completion of treatment
|
|
30 days following the completion of treatment
|
Cytostatic Overall Response Rate
Time Frame: From 6 months through 3.5 years after study entry
|
|
From 6 months through 3.5 years after study entry
|
Participant Response Rate in Relapsed or Refractory cHL.
Time Frame: Through 3.5 years from study entry or until disease progression
|
-Definitions per 2007 Cheson Lymphoma Response Criteria
|
Through 3.5 years from study entry or until disease progression
|
Time to Progression (TTP).
Time Frame: Through 3.5 years from study entry or until disease progression
|
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma.
|
Through 3.5 years from study entry or until disease progression
|
Overall Survival (OS)
Time Frame: Through 3.5 years from study entry or until disease progression
|
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause.
|
Through 3.5 years from study entry or until disease progression
|
Relapse Free Survival (RFS)
Time Frame: Through 3.5 years from study entry or until disease progression
|
Through 3.5 years from study entry or until disease progression
|
|
Event Free Survival (EFS).
Time Frame: Through 3.5 years from study entry or until disease progression
|
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death).
|
Through 3.5 years from study entry or until disease progression
|
Duration of Response
Time Frame: Through 3.5 years from study entry or until disease progression
|
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started
|
Through 3.5 years from study entry or until disease progression
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Todd Fehniger, M.D., Ph.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004 Apr;4(4):314-22. doi: 10.1038/nrc1323. No abstract available.
- Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 6, 2007
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
October 4, 2007
First Submitted That Met QC Criteria
October 4, 2007
First Posted (Estimate)
October 5, 2007
Study Record Updates
Last Update Posted (Actual)
November 6, 2017
Last Update Submitted That Met QC Criteria
October 5, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Hodgkin Disease
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- 07-0233 / 201104227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin Disease
-
Tessa TherapeuticsActive, not recruitingHodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, PediatricUnited States
-
Tessa TherapeuticsBristol-Myers SquibbActive, not recruitingClassical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease RefractoryUnited States
-
Shandong Provincial HospitalUnknownLymphoma, Non-Hodgkin;Hodgkin DiseaseChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
AkesoPeking University Cancer Hospital & InstituteRecruiting
-
Stanford UniversityCompletedLymphoma | Hodgkin Disease | Lymphoma, Hodgkin Disease | Lymphoma: HodgkinUnited States
-
Grupo Argentino de Tratamiento de la Leucemia AgudaTakedaRecruitingRefractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, AdultArgentina
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, France, Canada, Belgium, Italy
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, Canada
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance